Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-116 + ivonescimab in advanced non-small cell lung cancer
CTR20262242Phase 2Active
- Sponsor
- PuZhong Discovery
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-116, ivonescimab in non-small cell lung cancer (NSCLC), sponsored by PuZhong Discovery. Started Jun 2026; status: active.
02
Drugs
AMT-116ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262242.